News
Recursion Pharma has agreed to merge with rival AI-powered drug discovery firm Exscientia in an all-stock deal valued at $688 million ...
Find the latest on short interest, settlement dates, average share volume, and days to cover for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback